Tags

Type your tag names separated by a space and hit enter

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Blood. 2020 05 21; 135(21):1912-1915.Blood

Links

  • PMC Free PDF
  • Publisher Full Text

    • Authors+Show Affiliations

    Treon SP
    Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
    Castillo JJ
    Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
    Skarbnik AP
    Lymphoproliferative Disorders Program, Novant Health, Charlotte, NC; and.
    Soumerai JD
    Department of Medicine, Harvard Medical School, Boston, MA. Massachusetts General Hospital, Boston, MA.
    Ghobrial IM
    Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
    Guerrera ML
    Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
    Meid K
    Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
    Yang G
    Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.

    MeSH

    Agammaglobulinaemia Tyrosine KinaseAgedBetacoronavirusCoronavirus InfectionsFemaleHumansLung InjuryMaleMiddle AgedPandemicsPneumonia, ViralProtein Kinase InhibitorsPyrazolesPyrimidinesWaldenstrom Macroglobulinemia

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    32302379

    Citation

    Treon, Steven P., et al. "The BTK Inhibitor Ibrutinib May Protect Against Pulmonary Injury in COVID-19-infected Patients." Blood, vol. 135, no. 21, 2020, pp. 1912-1915.
    Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912-1915.
    Treon, S. P., Castillo, J. J., Skarbnik, A. P., Soumerai, J. D., Ghobrial, I. M., Guerrera, M. L., Meid, K., & Yang, G. (2020). The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood, 135(21), 1912-1915. https://doi.org/10.1182/blood.2020006288
    Treon SP, et al. The BTK Inhibitor Ibrutinib May Protect Against Pulmonary Injury in COVID-19-infected Patients. Blood. 2020 05 21;135(21):1912-1915. PubMed PMID: 32302379.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. AU - Treon,Steven P, AU - Castillo,Jorge J, AU - Skarbnik,Alan P, AU - Soumerai,Jacob D, AU - Ghobrial,Irene M, AU - Guerrera,Maria Luisa, AU - Meid,Kirsten, AU - Yang,Guang, PY - 2020/4/18/pubmed PY - 2020/6/2/medline PY - 2020/4/18/entrez SP - 1912 EP - 1915 JF - Blood JO - Blood VL - 135 IS - 21 SN - 1528-0020 UR - https://www.unboundmedicine.com/medline/citation/32302379/full_citation L2 - https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2020006288 DB - PRIME DP - Unbound Medicine ER -